Jpmorgan Chase & CO Pds Biotechnology Corp Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 619 shares of PDSB stock, worth $575. This represents 0.0% of its overall portfolio holdings.
Number of Shares
619
Previous 619
-0.0%
Holding current value
$575
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding PDSB
# of Institutions
60Shares Held
7.71MCall Options Held
98.2KPut Options Held
0-
Armistice Capital, LLC New York, NY2.24MShares$2.08 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.95MShares$1.81 Million0.0% of portfolio
-
Ubs Group Ag543KShares$505,0090.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$452,8790.0% of portfolio
-
Geode Capital Management, LLC Boston, MA418KShares$388,6780.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $26.5M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...